Therapeutic improvement of colonic anastomotic healing under complicated conditions: A systematic review

Table 3 Studies on therapeutic compounds in obstructive colon and obstructive jaundice models

Ref.	Compound	Time of administration	Species	Sex	Sample size1	Dosage	Route	Test	Test day	Effect2
Erbil et al[23]	PI	Preoperative	Rat	M	144	103	Lavage	BPR	3/6	↑ 44/↑ 42
	L-NAME					0.13				↓ 26/↓ 28
Aguilar-Nascimento et al[60]	PI	Preoperative	Rat	M	40	103	Lavage	BPR	3/6	NS/↑ 41
								BST		NS/↑ 28
Faruquzzaman et al[63]	EPO	Postoperative	Guinea pig	M	20	5004	SC	BPR	7	↑ 15
Moran et al[61]	EPO	Postoperative	Rat	M	20	5004	SC	BPR	7	↑ 12
Galanopoulos et al[62]	Iloprost	Postoperative	Rat	M	40	0.0025	IP	BPR	4/8	↑ 115/↑ 74
								AL		NS/NS
6Gulcelik et al[17]	GM-CSF	Intraoperative	Rat	M	44	0.0505	LO	BPR	3	↑ 24

¹Total number of animals;

²↑% increase (P < 0.05) or ↓% decrease (P < 0.05) vs controls;

³%-solution;

⁴IU/kg;

⁵mg/kg;

⁶Model of obstructive jaundice. AL: Anastomotic leakage; BPR: Bursting pressure; BST: Breaking strength; EPO: Erythropoietin; GM-CSF: Granulocyte macrophage-colony stimulating factor; IP: Intraperitoneal; L-NAME: NG-nitro-L-arginine methyl ester; LO: Local; M: Male; NS: Not statistically significant; PI: Povidone iodine; SC: Subcutaneous.